Gilead said that the $11.2 billion internal R&D asset cost resulting from the acquisition in the second quarter resulted in a one-time profit and loss of approximately $9.12 per share corresponding to GAAP standards and adjusted earnings per share, including the tax impact of related transactions.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.